Clinical Trials Browser

Phase 2 × Unknown × aldesleukin × Clear all

NCT04383067 2021-02-11

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Phase 2 Unknown

Carcinoma, Transitional Cell

NCT01274273 2014-12-02

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell

NCT00002846 2013-12-19

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002847 2013-12-19

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00080977 2013-12-19

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002589 2013-12-18

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003181 2013-12-04

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003090 2013-11-06

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00003604 2013-11-06

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003664 2013-11-06

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003743 2013-09-17

Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation

Phase 2 Unknown

Neuroblastoma